tbuckley/cabot-search huggingface dataset:
Abstract 9292: Effect of High-Pain versus Low-Pain Structured Exercise on Walking Ability in People with Intermittent Claudication: A Systematic Review and Network Meta-Analysis
Authors: Jemma Perks, Francesco Zaccardi, Craig Paterson, John S Houghton, Andrew T Nickinson, Coral J Pepper, Tom Yates, Robert Sayers
Journal: Circulation (2021)

Introduction: Guidance for exercise and pain in intermittent claudication recommends structured exercise programs at moderate-maximum pain, which may overlook the benefit of structured low-pain exercise on walking ability. We undertook a network meta-analysis to determine the comparative benefits of structured high-pain exercise and low-pain exercise, and usual-care control, to identify which has the largest effect on walking ability in people with intermittent claudication. Methods and Results: We searched nine electronic databases; additional trials (RCTs) were identified by hand-searching bibliographies from included studies, relevant reviews and meta-analyses. RCTs were included if: they involved adults with intermittent claudication; included at least two of following arms structured low-pain exercise, structured-high pain exercise or a usual-care control; they had a maximal or pain free treadmill walking outcome. This search resulted in the inclusion of 14 studies (n = 657), reporting the comparison of 9 high-pain arms, 4 low-pain arms, and 13 usual-care arms for maximal walking ability (MWA); and 7 high-pain arms, 4 low-pain arms and 11 usual-care arms for pain free walking ability (PFWA). Results were pooled using SMD. Structured low-pain exercise had a large positive effect on MWA (SMD: 2.23; 95% CI: 1.11 to 3.35) and a large positive effect on PFWA (2.26;1.26 to 3.26) when compared to usual-care control; structured high-pain exercise had a large positive effect on MWA (SMD: 0.95; 95% CI: 0.20 to 1.70) and a moderate positive effect on PFWA (0.77; 0.01 to 1.53) when compared to usual-care control; and structured low-pain exercise, compared to structured high-pain exercise showed a large positive effect in favour of low-pain exercise on MWA (SMD: 1.28, 95% CI: -0.07 to 2.62) and PFWA (1.50; 0.24 to2.75). Conclusions: Our findings support the provision of structured high- and low-pain exercise to improve walking ability in people with intermittent claudication over usual-care alone, with low-pain exercise appearing to have a larger effect. Large head-to-head RCTs are required to confirm the efficacy and safety of different structured exercise programmes prescribed using pain on walking ability in people with intermittent claudication.
Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia
Authors: Andrew Matthews, Alexander E. Perl, Selina M. Luger, Daria V. Babushok, Noelle V Frey, Saar Gill, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, David L. Porter, Edward A. Stadtmauer, Alison W. Loren, Vikram R Paralkar, Ivan Maillard, David Margolis, Keith W. Pratz
Journal: Blood (2021)
An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)
Authors: Lydia Scarfo, Elisa Albi, Francesca M. Quaglia, Roberto Marasca, Alessandro Sanna, Roberta Murru, Luca Laurenti, Gianluca Gaidano, Donato Mannina, Massimo Gentile, Caterina Patti, Gianluigi Reda, Alfonso Piciocchi, Paola Fazi, Stefano Soddu, Daniela Pietrasanta, Lorella Orsucci, Stefano Molica, Andrea Ferrario, Angela Ferrari, Paolo Sportoletti, Ilaria Angeletti, Sara Galimberti, Annalisa Chiarenza, Francesca Morelli, Francesca Mauro, Antonio Cuneo, Paolo Ghia
Journal: Blood (2021)
Abstract 10619: Determination of Cost Drivers and Variation Associated with Isolated Aortic Valve Replacement Surgery: Evaluating the Impact of Interval Feedback and Barriers and Facilitators of Cost Awareness among Cardiac Surgeons and Health Care Providers
Authors: Sophia Roy, Ryan Gainer, Gregory Hirsch
Journal: Circulation (2021)

Introduction: Marked variation among surgeons and relevant health care providers (HCPs) in aortic valve replacement (AVR) costs was demonstrated. Despite presentation of these data to HCPs, cost variation persists. We sought input from cardiac HCPsregarding intraoperative cost awareness, decision making and potential motivators towards greater cost consideration. Objectives: Three fold purpose: I) Determine the primary intraoperative cost drivers of performing an isolated AVR in a single-center Canadian hospital, II) Evaluate the impact of communicating cost and driver variability on decision making, and III) Identify the barriers and facilitators of incorporating cost considerations in isolated AVRs among HCPs. Methods: From May 2017-May 2019, data was collected on AVR cost drivers (n=216). There were three phases of data feedback to HCPs. Separate focus groups were held (Phase III) for cardiac HCPs including surgeons, anesthesiologists, perfusionists , residents, and OR nurses (n=27). Semi-structured interviews were used to elicit provider perspectives. Transcribed audio data was analyzed through the use of thematic analysis to develop a core set of common and comprehensive themes. Results: Data collection demonstrated marked inter-surgeon variation around the surgical costs of procedures. After feedback to HCPs, variation persisted and the median cost for AVRs increased. Five themes were identified from HCP groups: cost awareness, intraoperative decision making, influence surrounding intraoperative cost decision making, provider-based motivation for implementing intraoperative cost decision making, and cost drivers for an AVR. Conclusions: No difference in cost or variation before and after data feedback to HCPs was insufficient to impact surgeon’s behaviour in case costing, which motivated the qualitative work in the form of focus groups. HCPs demonstrated low cost awareness regarding cost drivers of AVRs. They expressed interest in engaging in cost decision making that was informed by cost containment. Measures such as listing the price of cost drivers in the OR and providing cost feedback could potentially encourage engagement in cost decision making for AVRs.
The Rate of Cellular Energy Production of Muscle Cells Is Attenuated By Carnitine Intracellular Deficiency Caused By Imatinib Treatment
Authors: Pavel Burda, Alzbeta Hlavackova, Vaclava Polivkova, Nikola Curik, Hana Klamová, Jitka Koblihova, Jiri Suttnar, Katerina Machova
Journal: Blood (2021)
Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission
Authors: Shaun Fleming, Cheng-Hong Tsai, Hartmut Döhner, Konstanze Döhner, Elli Papaemmanuil, Hwei-Fang Tien, John Reynolds, Andrew H. Wei, Hsin-An Hou
Journal: Blood (2021)
Pyrroline-5-Carboxylate Reductase 1: A Novel Target for Sensitizing Myeloma to Cytotoxic Agents By Inhibition of PRAS40-Mediated Protein Synthesis
Authors: Inge Oudaert, Hatice Satilmis, Philip Vlummens, Anke Maes, Elke De Bruyne, Karin Vanderkerken, Sarah-Maria Fendt, Kim De Veirman, Eline Menu
Journal: Blood (2021)
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Authors: Jessica K. Lee, Mehlika Hazar-Rethinam, Brennan Decker, Ole Gjoerup, Russell W. Madison, Daniel S. Lieber, Jon H. Chung, Alexa B. Schrock, James Creeden, Jeffrey Venstrom, Brian Alexander, Geoffrey R. Oxnard
Journal: Clinical Cancer Research (2021)

Abstract Purpose: Oncogenic kinase fusions are targetable with approved and investigational therapies and can also mediate acquired resistance (AR) to targeted therapy. We aimed to understand the clinical validity of liquid biopsy comprehensive genomic profiling (CGP) to detect kinase fusions pan tumor. Experimental Design: CGP was performed on plasma and tissue samples during clinical care. All exons plus selected introns of 16 kinases involved in oncogenic fusions (ALK, BRAF, EGFR, ERBB2, FGFR1/2/3, MET, NTRK1/2/3, PDGFRA/B, RAF1, RET, and ROS1) were sequenced to capture fusions, including well-characterized and novel breakpoints. Plasma circulating tumor DNA (ctDNA) fraction was estimated to inform sensitivity. Results: Of 36,916 plasma cases, 32,492 (88%) had detectable ctDNA. Kinase fusions were detected in 1.8% of ctDNA-positive cases (571/32,492) and were most prevalent in patients with cholangiocarcinoma (4.2%), bladder cancer (3.6%), and non–small cell lung cancer (NSCLC; 3.1%). Of the 63 paired patient samples that had tissue and ctDNA specimens collected within 1 year and with estimated plasma ctDNA fraction &amp;gt;1%, fusions were detected in 47 of 51 (92%) liquid specimens with a fusion in the tissue sample. In 32 patients with fusions detected in liquid but not in tissue, 21 (66%) had evidence of putative acquired resistance. Conclusions: Targetable kinase fusions are identified in ctDNA across cancer types. In pairs with tissue-identified fusions, fusion detection in ctDNA is reliable with elevated ctDNA fraction. These data support the validity of CGP to enable ctDNA-based fusion detection for informing clinical care in patients with advanced cancer.
Prospective Associations of Early Pregnancy Metal Mixtures with Mitochondria DNA Copy Number and Telomere Length in Maternal and Cord Blood
Authors: Anna R. Smith, Pi-I D. Lin, Sheryl L. Rifas-Shiman, Mohammad L. Rahman, Diane R. Gold, Andrea A. Baccarelli, Birgit Claus Henn, Chitra Amarasiriwardena, Robert O. Wright, Brent Coull, Marie-France Hivert, Emily Oken, Andres Cardenas
Journal: Environmental Health Perspectives (2021)

Metal exposure during pregnancy influences maternal and child health. Oxidative stress and inflammation may mediate adverse effects of heavy metals, whereas essential metals may act as antioxidants. Mitochondrial DNA is a prime target for metal-induced oxidative damage. Telomere dysfunction is attributed to imbalances between reactive oxidant species and antioxidants.We evaluated individual and joint associations of prenatal metals with mitochondrial DNA copy number (mtDNAcn) and telomere length (TL) in maternal and cord blood as biomarkers of inflammation and oxidative stress.We measured six nonessential metals (arsenic, barium, cadmium, cesium, lead, mercury) and four essential metals (magnesium, manganese, selenium, zinc) in first-trimester maternal red blood cells in Project Viva, a U.S. prebirth cohort. We measured relative mtDNAcn (n=898) and TL (n=893) in second-trimester maternal blood and mtDNAcn (n=419) and TL (n=408) in cord blood. We used multivariable linear regression and quantile g-computation to estimate associations between prenatal metals and the biomarkers. We used generalized additive models and Bayesian kernel machine regression to examine nonlinearity and interactions.A 2-fold increase in maternal magnesium was associated with lower maternal [β=-0.07, 95% confidence interval (CI): -0.10, -0.01] and cord blood (β=-0.08, 95% CI: -0.20, -0.01) mtDNAcn. Lead was associated with higher maternal mtDNAcn (β=0.04, 95% CI: 0.01, 0.06). Selenium was associated with longer cord blood TL (β=0.30, 95% CI: 0.01 0.50). An association was observed between the nonessential metal mixture and higher maternal mtDNAcn (β=0.04, 95% CI: 0.01, 0.07). There was a nonlinear relationship between cord blood mtDNAcn and magnesium; maternal mtDNAcn and barium, lead, and mercury; and maternal TL and barium.Maternal exposure to metals such as lead, magnesium, and selenium was associated with mtDNAcn and TL in maternal second trimester and cord blood. Future work will evaluate whether these biomarkers are associated with child health. https://doi.org/10.1289/EHP9294.
WITHDRAWN: lncRNA Linc00173 modulates glucose metabolism and multidrug chemoresistance in SCLC: Potential molecular panel for targeted therapy
Authors: Shuyu Wang, Fanrui Zeng, Shumei Liang, Qiuping Wang, Yang Wen, Qiongyao Wang, Jiexia Zhang, Man Li, Shun Fang, Ting Wei, Minglun Li, Farkhad Manapov, Jian Zhang, Linlang Guo
Journal: Molecular Therapy (2021)
Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC
Authors: Rebeca Bailen, Maria Jesus Pascual-Cascon, Manuel Guerreiro, Lucía López Corral, Anabelle Chinea, Arancha Bermúdez, Antonia Sampol, Inmaculada Heras, Estefanía García-Torres, Melissa Torres, Jose J. Rifon Roca, Beatriz Herruzo, Jaime Sanz, Marta Fonseca, Pilar Herrera, Mercedes Colorado, Leyre Bento, Oriana López-Godino, Carmen Martin Calvo, Gillen Oarbeascoa, Jose L. Diez-Martin, Mi Kwon
Journal: Blood (2021)
Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Michael J Buege, Phuong Dao, Raymond G Dematteo, Andréa LeVoir, Terry Pak, Connie Lee Batlevi, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Erel Joffe, William T Johnson, Niloufer Khan, Anita Kumar, Christina Y. Lee, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, Colette Owens, M. Lia Palomba, David J. Straus, Gottfried von Keudell, Andrew D. Zelenetz, Christian Grommes, Craig S. Sauter, Gilles Salles, Lorenzo Falchi
Journal: Blood (2021)
Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial
Authors: Maureen Achebe, Hoda Hassab, Salam Alkindi, R. Clark Clark Brown, Paul Telfer, Bart J. Biemond, Victor R. Gordeuk, Thokozeni Lipato, Margaret Tonda, Sarah Gray, Joanna Howard
Journal: Blood (2021)
Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab
Authors: Allison C. Rosenthal, Colleen Ramsower, Raphael Mwangi, Matthew J. Maurer, Diego Villa, Timothy J. McDonnell, Andrew L. Feldman, Thomas M. Habermann, Jonathon B. Cohen, Ryan S. Robetorye, Elías Campo, Eva Giné, James R. Cook, Brian T. Hill, Philipp Raess, German Ott, Alexander Reichart, David W. Scott, Lisa M. Rimsza
Journal: Blood (2021)
Autoimmunity May Explain Diabetes in a Subset of Patients With Recurrent Acute and Chronic Pancreatitis: A Pilot Study
Authors: Dhiraj Yadav, David C. Whitcomb, Gong Tang, Adam Slivka, Melena Bellin, Samer AlKaade, Stephen T. Amann, Michelle A. Anderson, Peter Banks, Darwin Conwell, Randall E. Brand, Gregory A. Cote, Joseph Romagnuolo, Christopher E. Forsmark, Timothy Gardner, Andres Gelrud, Nalini Guda, Michele Lewis, Thiruvengadam Muniraj, Bimaljit S. Sandhu, Stuart Sherman, Vikesh Singh, C. Mel Wilcox
Journal: Clinical Gastroenterology and Hepatology (2021)
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
Authors: Vishal N Rao, Evan Murray, Javed Butler, Lauren B Cooper, Zachary L Cox, Mona Fiuzat, Jennifer B Green, JoAnn Lindenfeld, Darren K McGuire, Michael E Nassif, Cara O'Brien, Neha Pagidipati, Kavita Sharma, Muthiah Vaduganathan, Orly Vardeny, Gregg C Fonarow, Robert J Mentz, Stephen J Greene
Journal: Journal of the American College of Cardiology (2021)
Current Status of Benzodiazepines
Authors: Jan Koch-Weser, David J. Greenblatt, Richard I. Shader, Darrell R. Abernethy
Journal: New England Journal of Medicine (1983)

Clinical Use of BenzodiazepinesAnxietySince 1977, several new benzodiazepines have been marketed in the United States for the treatment of anxiety syndromes67 68 69 70 71 (Table 1). These drugs may offer some subtle clinical options. Prazepam, for example, may cause less drowsiness after single doses than do comparable doses of other benzodiazepines because of the slow appearance of desmethyldiazepam in the blood.72 Some clinical studies suggest a reduced incidence of sedation during treatment with lorazepam and alprazolam — benzodiazepines that have an intermediate half-life — possibly because the extent of drug accumulation is reduced; however, this is not a consistent finding.69 , 70 In . . .
Promotech: a general tool for bacterial promoter recognition
Authors: Ruben Chevez-Guardado, Lourdes Peña-Castillo
Journal: Genome biology (2021)

Abstract Promoters are genomic regions where the transcription machinery binds to initiate the transcription of specific genes. Computational tools for identifying bacterial promoters have been around for decades. However, most of these tools were designed to recognize promoters in one or few bacterial species. Here, we present Promotech, a machine-learning-based method for promoter recognition in a wide range of bacterial species. We compare Promotech’s performance with the performance of five other promoter prediction methods. Promotech outperforms these other programs in terms of area under the precision-recall curve (AUPRC) or precision at the same level of recall. Promotech is available at https://github.com/BioinformaticsLabAtMUN/PromoTech .
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Authors: Arnon Nagler, Myriam Labopin, Pietro Pioltelli, Mutlu Arat, Ibrahim Yakoub-Agha, Aleksandr D. Kulagin, Emanuele Angelucci, Hakan Ozdogu, Antonio Risitano, Fabio Ciceri, Zubeyde Nur Ozkurt, Jaime Sanz, Eolia Brissot, Zinaida Peric, Sebastian Giebel, Mohamad Mohty
Journal: Blood (2021)
Abstract 10890: Microbial Community Structure of Dental Plaque, Blood and Cerebral Thrombus in Patients with Acute Ischemic Stroke
Authors: Mengzhen Li, Bin Xiao, Hanzi Qiao, Bin Wu, Jiecong Yang, Qihua Guo, Baoying Gong, Ying Li, Jianwen Guo
Journal: Circulation (2021)

Introduction: Epidemiological investigations have demonstrated a strong link between periodontal disease and stroke. However, relevant microbiological researches are still lacking at present. This study aimed to investigate the microbial composition of dental plaque, blood and cerebral thrombus in patients with acute ischemic stroke (AIS). Hypothesis: We hypothesized that there was a possible translocation for oral bacteria from periodontal pocket into blood and subsequently involving in the process of cerebral thrombus formation. Methods: Thrombus aspirates, dental plaque and venous blood samples were taken from 13 patients (11 males, 65.5 ± 10.7 years) with AIS. Microbiota was analyzed using high-throughput 16S rRNA gene amplicon sequencing and bioinformatics analyses. Results: Proteobacteria was the most predominant phylum in dental plaque, blood and thrombus. There were no statistic difference in alpha (Shannon and Simpson indexes) and beta diversity (weighted UniFrac distance metric) among dental plaque, blood and thrombus, suggesting a high similarity in their microbial compositions. While, an increased trend of species diversity from supragingival plaque, subgingival plaque, blood to thrombus was observed. Besides, several microbes in thrombus were found to be correlated with plasma coagulation levels, including genera Porphyromonas , which is the common cause of periodontal infection. SourceTracker analysis suggested that about 58% microbial population in blood were oral origin and about 75% microbial population in cerebral thrombi were blood origin. Conclusions: This study described the bacterial profile of dental plaque, blood and thrombus in AIS patients. Our study suggested that some of the bacteria in cerebral thrombus might be derived from the blood and oral cavity and there was a close microbial community compositional relationship among these samples.
Sickle cell disease: inquiry finds serious care failings and racism towards patients
Authors: Elisabeth Mahase
Journal: BMJ (2021)

Patients with sickle cell disease admitted into general wards or attending emergency departments in England face substandard care and negative attitudes, with some exposed to blatant racism, an inquiry has found.1

The No One’s Listening report was triggered by a coroner’s report into the avoidable death of 21 year old Evan Nathan Smith in North Middlesex in April 2019. It is based on evidence sessions with patients, clinicians, and politicians and was jointly published by the All Party Parliamentary Group on Sickle Cell and Thalassaemia and the charity Sickle Cell Society.

The …
Efficient Targeting of CD38 in Mature T-Cell Neoplasms with Daratumumab and Allogeneic NK Cells
Authors: William T. Johnson, Colleen Isabelle, Ashley N Vogel, Jonathan E Brammer, Amy E Boles, Kathleen McConnell, Robyn Berge, Liam Nisenfeld, Guldeep Uppal, Jerald Gong, Nitin Chakravarti, Pierluigi Porcu, Anjali Mishra
Journal: Blood (2021)
Luspatercept Redistributes Body Iron to the Liver in Transfusion-Dependent-Thalassemia (TDT) during Erythropoietic Response
Authors: Maciej W. Garbowski, Manuel Ugidos, Alberto Risueño, Rajasekhar N.V.S. Suragani, Jeevan K. Shetty, Sadanand Vodala, Anjan Thakurta, Martin Schwickart, John B. Porter
Journal: Blood (2021)
Supporting healthcare workers involved in medical errors: from “second victims” to “resilient warriors”
Authors: Eugenia I Gorlin, Vera Békés, Laura M Mazer
Journal: BMJ (2021)

Although Clarkson and colleagues compellingly criticise the term “second victim” from a patient perspective,1 others have argued for retaining this framework given its potential to mitigate the pervasive mental health effects of adverse events for medical providers.2 But do second victim support programmes really achieve this aim?

A hard won lesson of psychologists’ work with military personnel who feel responsible …
A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Authors: Matthew J. Frigault, Kathleen M.E. Gallagher, Marc Wehrli, Betsy Valles, Keagan Casey, Kevin Lindell, Michael Trailor, Hana Cho, Jami L. Brown, Nora K. Horick, Justin Chou, Rhine R. Shen, Simone Filosto, Adrian Bot, Marcela V. Maus
Journal: Blood (2021)
A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Torben Plesner, Simon J Harrison, Hang Quach, Cindy H. Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Teiko Sumiyoshi, Karen Miller, Eunpi Choi, Fredrik H. Schjesvold
Journal: Blood (2021)
The Time Machine framework: monitoring and prediction of biodiversity loss
Authors: Niamh Eastwood, William A. Stubbings, Mohamed A. Abou-Elwafa Abdallah, Isabelle Durance, Jouni Paavola, Martin Dallimer, Jelena H. Pantel, Samuel Johnson, Jiarui Zhou, J. Scott Hosking, James B. Brown, Sami Ullah, Stephan Krause, David M. Hannah, Sarah E. Crawford, Martin Widmann, Luisa Orsini
Journal: Trends in Ecology & Evolution (2021)
Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases
Authors: Scott C. Ritchie, Samuel A. Lambert, Matthew Arnold, Shu Mei Teo, Sol Lim, Petar Scepanovic, Jonathan Marten, Sohail Zahid, Mark Chaffin, Yingying Liu, Gad Abraham, Willem H. Ouwehand, David J. Roberts, Nicholas A. Watkins, Brian G. Drew, Anna C. Calkin, Emanuele Di Angelantonio, Nicole Soranzo, Stephen Burgess, Michael Chapman, Sekar Kathiresan, Amit V. Khera, John Danesh, Adam S. Butterworth, Michael Inouye
Journal: Nature Metabolism (2021)
Abstract 14738: Actimis Trial: Safety and Efficacy Evaluation of ACT017, a Novel Antiplatelet Agent on Top of Acute Ischemic Stroke Standard of Care
Authors: Mikael Mazighi, Yannick Pletan, Andrea Comenducci, Bertrand Lapergue, Danilo Toni, Martin Koehrmann, Robin Lemmens, Philippe Lyrer, Carlos Molina, Gilles Avenard
Journal: Circulation (2019)

Introduction: Standard of care (SoC) for acute ischemic stroke (AIS) patients, includes intravenous tPA administration and mechanical thrombectomy. SoC has significant limitations with <10% of AIS ...